Atropine Eyedrops for Myopia Progression in Children and Adolescents (MODERATO STUDY)
Key facts
- Who runs it
- Ocus Innovation Ireland Limited
- Where
- Albania, Italy, Poland, Spain, and United Kingdom11 sites in 5 countriesChoose a country to see its sites
- Trial code
- NCT07028827
- EU 2023-510439-13-00
- U1111-1304-3811
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 234 people, planned
- Started
- 1 Sept 2025
- Expected to end
- 31 Dec 2027
- Type of study
- Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- 0.05% atropine eye drops
- 0.025% atropine eye drops
- placebo eye drops
- Record updated
- 11 February 2026
Who can take part
- Age
- 3 years to 17 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 22 criteriaShow less
Who can take part
- Males and females, aged from 3 to less than 18 years
- Subjects showing myopia with a spherical equivalent refraction of both eyes at least -0.75 D at baseline
- The intraocular pressure in each eye must be equal or less than 21 mmHg
- The parents or the legal representative must be informed about the clinical trial and must sign the informed consent form. The exception to consider is related to the individuals aged above 16 years only in the UK, who can provide their own consent according to the local regulations
- Women with childbearing potential (WOCBP) (after menarche) who have a negative highly sensitive urine dipstick pregnancy test. Additional pregnancy testing during the study will be conducted at visits 1, 2, 3, 4, 5, 6
- WOCBP or males who are using a highly effective birth control method to prevent pregnancies. Eligible highly effective contraceptive methods for WOCBP are combined (which contain estrogen and progestogen) hormonal contraception associated with inhibition of ovulation (oral, intravaginal (inside of the vagina), transdermal (through the skin)); progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable); intrauterine device (small devices that are placed inside uterus to prevent pregnancies); intrauterine hormone-releasing system. Sexual abstinence represents a highly effective contraceptive method, if in line with the subject's normal habits
Who cannot take part
- Abnormalities in ocular biometry, except for axial length or previous intraocular or ocular laser/non-laser surgery
- Any treatment received for myopia within the past three months prior to inclusion in the study
- History of amblyopia or strabismus
- Presence of a history of a retinal dystrophy or systemic disorder that may predispose to severe myopia (e.g., Marfan syndrome, retinitis pigmentosa, Stickler syndrome, retinopathy of prematurity)
- History of glaucoma or narrow angles in the anterior chamber of the eye
- Conditions such as Down syndrome or spastic paralysis
- Known intolerance or allergies to atropine eye drops or hypersensitivity to any component of the atropine eye drops
- History of alcohol or drug abuse
- Anisometropia, meaning a significant difference in refractive power between the two eyes exceeding |1.5| D
- Refractive astigmatism exceeding |1.5| D
- Presence of ocular pathologies such as pathological myopia, corneal scars, or other anterior or posterior eye pathologies
- Pregnancy or breastfeeding
- Mental or emotional instability that could interfere with study procedures
- Lack of reliability or cooperation from the patient
- Other reasons, at the discretion of the investigator that may deem the subject's participation in the study inappropriate
- Patients who have consented to participate in the clinical trial, but do not meet one or more eligibility criteria required for participation in the trial during the screening procedures, and subsequently are not randomly assigned to the study treatment or entered in the study, are considered screening failures
The main criteria, as questions
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 3 and 17 years old?
This trial has no sites in United States.
It has sites in 5 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
Myopia, or shortsightedness, is a multifactorial disorder, governed by environmental and genetic factors.
Read full original descriptionShow less
Myopia is the most common ocular disorder worldwide with an increasing prevalence over the past few decades and affecting the quality of life and economic health of individuals worsening socio-economic problems.
Progressive myopia is nearly exclusively a condition of childhood and adolescence, as in most young adults, myopia has stabilized.
Myopia frequently appears in childhood, with a peak incidence occurring between 8 and 10 years of age.
The most used topical pharmacological intervention for managing childhood myopia progression is atropine, a non-selective muscarinic antagonist, which has been widely used in clinical trials in concentrations ranging from 0.01% to 1.0%.
Atropine is at present the agent with the highest efficacy and optimal safety profile to reduce myopia progression in children and adolescents.
MODERATO study, a phase III, prospective, multicentric, randomized, double blind, multiple doses, placebo-controlled parallel-group, adaptive study, aims to evaluate the efficacy and safety of 0.025% and 0.05% atropine eye drops in children and adolescents aged 3 to under 18 years old over a 24-month period, to understand its ability to manage and stop myopia getting worse. It will be conducted in 11 centers in Italy, Spain, Poland, the UK and Albania.
The 3 groups in the trial
- Group 1Treatment being tested
This group (N = 78 subjects) will be treated with 0.05% atropine eye drops
Treatment: 0.05% atropine eye drops
- Group 2Treatment being tested
This group (N = 78 subjects) will be treated with 0.025% atropine eye drops
Treatment: 0.025% atropine eye drops
- Group 3Placebo, for comparison
This group (N = 78 subjects) will be treated with placebo eye drops
Treatment: placebo eye drops
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Phase III, Randomized, Double-blind, Multiple Doses, Placebo-controlled, Parallel-group Adaptive Study to Evaluate the Efficacy and Safety of Atropine for the Treatment of Myopia Progression in Children and Adolescents (MODERATO Study)
- Criteria questions
- Built from NCT07028827, who can take part
- Record updated
- 11 February 2026